Volume 7 Supplement 1

VI Madrid Breast Cancer Conference: Changes in the treatment of breast cancer

Open Access

Role of translational studies in optimizing palliative chemotherapy

  • R Kramer1, 2
Breast Cancer Research20057(Suppl 1):S28

https://doi.org/10.1186/bcr1232

Published: 27 May 2005

Introduction

Patients with metastatic breast cancer have a highly variable clinical course. Systemic chemotherapy may decrease symptoms and prolong survival for some patients. However, others experience significant toxicity and achieve little benefit. Predictive markers are needed to determine which patients will benefit from particular chemotherapy agents and which should be offered novel therapeutics.

Methods

The English literature related to predictive markers for metastatic cancer was reviewed. Translational studies examining the potential role of tumor profiles in the selection of optimal chemotherapy agents were identified. Particular attention was paid to studies examining sensitivity and resistance to anthracyclines, taxanes, vinorelbine and capecitabine.

Conclusion

This paper will summarize the rapidly expanding data published to data and will discuss clinical trial designs that will facilitate future studies.

Authors’ Affiliations

(1)
Breast Care Center, Baylor College of Medicine
(2)
Visiting Professor, Hospital Universitario 12 de Octubre

Copyright

© BioMed Central 2005

Advertisement